

CombiGene celebrates International Epilepsy Day

The International Epilepsy Day is held on the second Monday of February each year. There are 50 million people in the world living with epilepsy, of which 81,000 lives in Sweden. The purpose of International Epilepsy Day is for all the world's epilepsy associations to jointly acknowledge and highlight the disease and its consequences. The day also includes coordinated information and education efforts to strengthen efforts worldwide for people with epilepsy.

International Epilepsy Day is a joint initiative between the International Bureau for Epilepsy (IBE) and the International League Against Epilepsy (ILAE) as well as their representation in 138 countries. With both national epilepsy federations and medical profession in close cooperation, alongside with cooperation with WHO and with IBE's consultative status in the UN ECOSOC, International Epilepsy Day is the most prestigious epilepsy activity in the world.

For more information, see:

<https://internationalepilepsyday.org/>

Source Svenska Epilepsiförbundet:

<https://bit.ly/3rtQgzl>



CombiGene's Karin Agerman talks about the possibilities of gene therapy at the Swedish Epilepsy Association's webinar on 8 February.

CombiGene is a Swedish gene therapy company that develops a gene therapeutic treatment for epilepsy. This development project is in

a late preclinical phase with the first human study scheduled for 2022. Karin Agerman, CombiGene's Chief Research & Development Officer has been invited to speak under the heading: Is gene therapy the future of treatment for epilepsy?

Information about the Swedish Epilepsy Association's webinar

Link to Webinar:

<https://bit.ly/3oRtcJo>

About CombiGene AB

CombiGene's vision is to offer patients affected by severe life-changing diseases opportunities for a better life through innovative gene therapies. CombiGene's business concept is to develop effective gene therapies for serious diseases that today lack adequate treatment methods. Research assets are taken in from a network of external researchers and developed further up to clinical concept verification. Drug candidates for common diseases will be co-developed and commercialized through strategic partnerships, while CombiGene may drive the development and commercialization in-house for medicines aimed at limited patient populations. The company is public and listed on the Nasdaq First North Growth Market and the company's Certified Advisor is FNCA Sweden AB, +46 (0)852 80 03 99, info@fnca.se.

For further information:

CombiGene AB (publ)
Jan Nilsson, CEO
Tel: +46 (0)704 66 31 63
jan.nilsson@combigene.com

Bert Junno, Chairman of the board
Tel: +46(0) 70 777 22 09
bert.junno@combigene.com

Please read *INGENIEIOUS*, a newsletter from CombiGene which contains general news and information that is judged not to have a significant effect on the share price. *INGENIEIOUS* and press releases are available at www.combigene.com